Nevro Management

Management criteria checks 1/4

Nevro's CEO is Kevin Thornal, appointed in Apr 2023, has a tenure of 1.08 years. total yearly compensation is $11.45M, comprised of 4.5% salary and 95.5% bonuses, including company stock and options. directly owns 0.71% of the company’s shares, worth €2.71M. The average tenure of the management team and the board of directors is 1.3 years and 5.2 years respectively.

Key information

Kevin Thornal

Chief executive officer

US$11.5m

Total compensation

CEO salary percentage	4.5%
CEO tenure	1.1yrs
CEO ownership	0.7%
Management average tenure	1.3yrs
Board average tenure	5.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Kevin Thornal's remuneration changed compared to Nevro's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$11m	US$516k	-US$92m

Compensation vs Market: Kevin's total compensation ($USD11.45M) is above average for companies of similar size in the German market ($USD993.35K).

Compensation vs Earnings: Insufficient data to compare Kevin's compensation with company performance.

CEO

Kevin Thornal (49 yo)

1.1yrs

Tenure

US$11,453,548

Compensation

Mr. Kevin R. Thornal serves as President & Chief Executive Officer at Nevro Corp. since April 24, 2023 and serves as its Director since May 2023. He joined Nevro Corp. on April 24, 2023. He serves as Acti...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kevin Thornal	President	1.1yrs	US$11.45m	0.71% $ 2.7m
Roderick MacLeod	Senior VP & CFO	3.9yrs	US$2.58m	0.052% $ 196.2k
Kashif Rashid	Senior VP of Corporate Development & Chief Legal Officer	6.4yrs	US$2.55m	0.12% $ 437.6k
Greg Siller	Senior VP & Chief Commercial Officer	less than a year	US$3.56m	no data
Richard Carter	Chief Accounting Officer	1.7yrs	no data	0.025% $ 94.8k
Christofer Christoforou	Senior Vice President of Technical Operations	1.3yrs	US$2.87m	no data
Geeta Kaveti	VP and Chief Compliance & Privacy Officer	1.3yrs	no data	no data
Meredith Vornholt	Vice President of Global Marketing	2.3yrs	no data	no data
Shana Ross	Senior VP & Chief Human Resources Officer	1.3yrs	no data	no data
David Caraway	Senior VP & Chief Medical Officer	10.1yrs	no data	no data
Donald Middlebrook	Senior Vice President of Clinical & Regulatory Affairs	1.3yrs	no data	no data
Peter Socarras	VP, General Counsel & Corporate Secretary	no data	no data	no data

1.3yrs

Average Tenure

51yo

Average Age

Experienced Management: 1N7's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Kevin Thornal	President	less than a year	US$11.45m	0.71% $ 2.7m
Frank Fischer	Independent Director	11.6yrs	US$246.99k	0.14% $ 525.6k
Susan Siegel	Independent Director	3.4yrs	US$242.99k	0.015% $ 56.0k
Shawn McCormick	Independent Director	9.7yrs	US$246.99k	0.055% $ 208.3k
Elizabeth Weatherman	Independent Director	5.2yrs	US$259.24k	0.13% $ 507.8k
D. Grossman	Non-Executive Chairman of the Board	5.2yrs	US$1.48m	0.52% $ 2.0m
Michael DeMane	Independent Lead Director	13.2yrs	US$284.99k	1.26% $ 4.8m
Kevin O'Boyle	Independent Director	5.2yrs	US$259.99k	0.048% $ 181.0k
Kirt Karros	Independent Director	less than a year	no data	no data
Karen Prange	Independent Director	4.4yrs	US$252.99k	0.022% $ 83.1k
Sridhar Kosaraju	Independent Director	2.6yrs	US$242.99k	0.030% $ 113.0k

5.2yrs

Average Tenure

62yo

Average Age

Experienced Board: 1N7's board of directors are considered experienced (5.2 years average tenure).

Nevro Management

Management criteria checks 1/4

Key information

Recent management updates

Nevro Corp., Annual General Meeting, May 23, 2024

Independent Director recently bought €160k worth of stock

Nevro Corp. Announces Executive Changes

Nevro Corp. Announces Executive Changes

General Counsel recently bought €95k worth of stock

Nevro Corp., Annual General Meeting, May 26, 2022

Recent updates

Nevro Corp. to Report Q1, 2024 Results on May 07, 2024

New minor risk - Shareholder dilution

Nevro Corp., Annual General Meeting, May 23, 2024

Full year 2023 earnings released: US$2.56 loss per share (vs US$0.085 profit in FY 2022)

Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Nevro Corp. to Report Q4, 2023 Results on Feb 21, 2024

Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain

Nevro Corp. Increases Revenue Guidance for the Full-Year 2023

Nevro Corp. Provides Revenue Guidance for the Fourth Quarter of 2023

Third quarter 2023 earnings released: US$0.65 loss per share (vs US$2.30 profit in 3Q 2022)

New major risk - Revenue and earnings growth

Nevro Corp. to Report Q3, 2023 Results on Nov 01, 2023

Nevro Corp. Announces New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy

Nevro Announces Launch of HFX Connect in Europe and CE Marking of Expanded Labelling for the HFX SCS system

Nevro Corp. Revises Earnings Guidance for the Full-Year 2023

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: US$0.69 loss per share (vs US$0.71 loss in 2Q 2022)

Independent Director recently bought €160k worth of stock

Nevro Corp. Announces Executive Changes

Nevro Corp. to Report Q2, 2023 Results on Aug 01, 2023

First quarter 2023 earnings released: US$0.98 loss per share (vs US$0.98 loss in 1Q 2022)

Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2023

Full year 2022 earnings released: EPS: US$0.085 (vs US$3.77 loss in FY 2021)

Nevro Corp. to Highlight New Clinical Evidence at the 2023 North American Neuromodulation Society 26th Annual Meeting

Nevro Corp. to Report Q4, 2022 Results on Feb 16, 2023

Third quarter 2022 earnings released: EPS: US$2.30 (vs US$1.44 loss in 3Q 2021)

Nevro Corp. Updates Earnings Guidance for the Year Ending December 31, 2022

Nevro Corp. Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic Pain

Nevro Corp. to Report Q3, 2022 Results on Nov 02, 2022

Nevro Corp. Announces American Association of Clinical Endocrinology Clinical Practice Guideline Has Been Updated to Include High-Frequency 10 kHz Spinal Cord Stimulation to Treat Painful Diabetic Neuropathy

Nevro Corp. Announces Executive Changes

Nevro Announces Multiple Positive Coverage Updates for the Treatment of Painful Diabetic Neuropathy

Second quarter 2022 earnings released: US$0.71 loss per share (vs US$0.62 loss in 2Q 2021)

Nevro Corp. Revises Earnings Guidance for the Full Year 2022

Nevro and Boston Scientific Corporation Announce the Settlement of Their Ongoing Intellectual Property Litigations

Nevro Corp. to Report Q2, 2022 Results on Aug 03, 2022

Nevro Corp. Announces the Complete 12-Month Results from the SENZA-PDN Randomized Controlled Trial

General Counsel recently bought €95k worth of stock

First quarter 2022 earnings released: US$0.98 loss per share (vs US$0.85 loss in 1Q 2021)

Nevro Corp. Provides Earnings Guidance for the Second Quarter of 2022; Reiterates Earnings Guidance for the Year 2022

Nevro Corp., Annual General Meeting, May 26, 2022

Nevro Corp. to Report Q1, 2022 Results on May 04, 2022

Chairman of the Board recently bought €187k worth of stock

Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Nevro Announces Publication of Twelve Month Data from SENZA-NSRBP Randomized Controlled Trial in Journal of Neurosurgery: Spine

Nevro Announces FDA Approval for Expanded Labeling for its 10 kHz High Frequency Spinal Cord Stimulation System for Treatment of Non-Surgical Refractory Back Pain (NSRBP)

Nevro Corp. Announces Clinical Data Presented at 2022 North American Neuromodulation Society (NANS) Annual Meeting Reinforce Significant and Durable Benefits of Nevro's 10 kHz Therapy

Nevro Corp. Announces Unitedhealthcare Coverage for High-Frequency 10 KHZ Therapy for the Treatment of Painful Diabetic Neuropathy

Independent Director recently bought €178k worth of stock

Nevro Corp. Announces Settlement of IP Litigation with Nalu Medical

Nevro Corp. Announces Three Important Clinical Data Publications for Treating Painful Diabetic Neuropathy with 10 kHz Therapy

General Counsel recently bought €176k worth of stock

Third quarter 2021 earnings released: US$1.44 loss per share (vs US$0.29 loss in 3Q 2020)

High number of new directors

Nevro Corp. Withdraws Full Year 2021 Guidance

Second quarter 2021 earnings released: US$0.62 loss per share (vs US$1.21 loss in 2Q 2020)

Nevro Corp. Provides Preliminary, Unaudited Revenue Guidance for the Second Quarter of 2021

Nevro Corp. SENZA-PDN Clinical Data Presentation at the American Diabetes Association 81st Scientific Sessions

Nevro Corp. Provides Earnings Guidance for the Second Quarter Ended June 30, 2021 and Full Year 2021

First quarter 2021 earnings released: US$0.85 loss per share (vs US$0.78 loss in 1Q 2020)

Nevro Corp. Provides Earnings Guidance for the Second Quarter Ended June 30, 2021

Nevro Introduces HFX, New Comprehensive Brand Identity Combining Nevro's Innovative Technologies, Advanced Therapies and End-To-End Patient Support

New 90-day low: €130

Full year 2020 earnings released: US$2.47 loss per share (vs US$3.37 loss in FY 2019)

Revenue beats expectations

New 90-day high: €151

Nevro to Highlight New Clinical Evidence at the 2021 North American Neuromodulation Society (NANS) Virtual Meeting

Nevro Corp. to Report Q4, 2020 Results on Feb 24, 2021